>　部門紹介　>　主な研究実績　>　2025年


2025年

◆発表論文(英文)

1. Constrictive Pericarditis in a Hemodialysis Patient Who Presented with Rapidly Progressive Pericardial Calcification: A Diagnostic Challenge – A Case Report.

Tsunematsu O, Takeda SI, Yamaguchi M, Kaneko M, Oe K, Murakami Y, Nagata D.

Case Rep Nephrol Dial. 2025 Feb 11;15(1):33-40.

 

2. Effects to cerebral oxygenation by arteriovenous fistula creation in patients with chronic kidney disease.

Mutsuyoshi Y, Ito K, Ookawara S, Ueda Y, Shindo M, Hirata M, Nonaka H, Morino J, Kaneko S, Kitano T, Miyazawa H, Hirai K, Morishita Y.

J Vasc Access. 2025 May;26(3):945-951. 

 

3. An Exploratory Single-Arm Clinical Trial on Eucommia Ulmoides Leaf Extract Effects on Blood Pressure, Oxidative Stress, and Atrial Natriuretic Peptide (ANP) in Individuals With and Without Chronic Kidney Disease.

Satonaka H, Yokoyama S, Ishimitsu A, Takahashi C, Rai T, Nagata D, Ishimitsu T, Tojo A.

Int J Nephrol. 2025 Jun 19.

 

4. NELL-1-positive membranous nephropathy following gastric cancer in an older living kidney donor: a case report.

Hashimoto M, Hishida E, Ono Y, Murakami T, Hirata M, Kinoshita M, Imai T, Akimoto T, Nagata D.

CEN Case Rep. 2025 Jun 24.

 

6. Severe hypercalcemia requiring emergency hemodialysis and multidrug therapy in a case of diffuse large B-cell lymphoma with multiple bone lesions.

Watanabe Y, Kaneko S, Yamamoto R, Ogishi T, Okamoto S, Yuyama K, Matsuoka A, Nakamura Y, Ando S, Ito K, Hirai K, Ookawara S, Morishita Y.

BMC Nephrol. 2025 Aug 25;26(1):488. 

 

7.  Comparative impact of hemodialysis and isolated ultrafiltration on vascular endothelial glycocalyx injury.

Masuda T, Okada H, Nagata D.

Ther Apher Dial. 2025 Aug;29(4):699-701

 

8. Low-potassium triggers tubular epithelial NLRP3/ASC-driven kidney inflammation independently of inflammasomes.

Komori S, Komada T, Matsumura T, Karasawa T, Miura Y, Baatarjav C, Gunji Y, Aizawa H, Mizushina Y, Fukushima N, Sugihara T, Ando S, Fujimura T, Nagata D, Takahashi M.

Am J Pathol. 2025 Sep 12.

 

9. Efficacy of dapagliflozin on uric acid in patients with moderate-to-severe chronic kidney disease.

Yanai K, Hirai K, Kitano T, Miyazawa H, Ito K, Ookawara S, Morishita Y.

Clin Exp Nephrol. 2025 Sep 18. 

 

10. Systolic blood pressure is associated with early and long-term changes in renal function in patients with dapagliflozin-treated moderate-to-advanced chronic kidney disease.

Yanai K, Hirai K, Kitano T, Miyazawa H, Ito K, Ookawara S, Morishita Y.

Clin Exp Nephrol. 2025 Sep;29(9):1200-1211.

 

11.  SGLT2 inhibitor requires co-administration with diuretics to effectively reduce interstitial fluid retention: the DAPA-BODY trial.

Masuda T, Asakura-Kinoshita M, Oka K, Ohara K, Sakai M, Miura M, Misawa K, Hirai K, Morinari M, Akimoto T, Shimada K, Nagata D, Morishita Y.

Hypertens Res. 2025 Oct 1. 

 

12. Clinicopathological Study on Endothelial Injury in Severe Glomerular Microangiopathy Induced by Ramucirumab.

Sakai M, Watanabe M, Hayashi Y, Sugano M, Horiguchi T, Nishikawa S, Yamaguchi A, Naiki H,
Okada H, Masuda T, Yoshida H.

Intern Med. 2025;64(13):2024-2030

 

主な研究実績